Drug Urothelial Cancer

Jelmyto

Payments companies reported to CMS as associated with Jelmyto. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.4Massociated payments (2023-2025)
6,653clinicians with associated payments
2companies reporting

By year

2023 $407K
2024 $659K
2025 $341K

Payments reported as associated with Jelmyto, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Urology $1.2M
Physician Assistant $48K
Family $43K
Surgery $32K
Nurse Practitioner $24K
Adult Health (Nurse Practitioner) $10K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Jelmyto

These are the largest totals companies reported as associated with Jelmyto. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Katie Murray New York, NY Urology $284,026.48
Vahan Kassabian Roswell, GA Urology $59,820.84
Marc Bjurlin Kinston, NC Urology $49,323.78
Vignesh Packiam Iowa City, IA Urology $41,788.15
Jennifer Linehan Santa Monica, CA Urology $41,076.96
Ravi Munver Hackensack, NJ Urology $31,188.32
Zachary Klaassen Augusta, GA Surgery $29,702.19
Sandip Prasad Charleston, SC Urology $28,011.32
Yair Lotan Dallas, TX Urology $26,058.52
Rian Dickstein Hanover, MD Urology $21,548.46

Prescribed Jelmyto?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.